2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Matthew C. Ward, MD, discusses considerations for salvage radiation therapy in prostate cancer.
This is a modal window.
Beginning of dialog window. Escape will cancel and close the window.
End of dialog window.
This is a modal window. This modal can be closed by pressing the Escape key or activating the close button.
Matthew C. Ward, MD, radiation oncologist, Levine Cancer Institute, Atrium Health, discusses considerations for salvage radiation therapy in prostate cancer.
In considering salvage radiation for a patient with prostate cancer, it is critical to look at the patient’s pathology report, margin status, disease stage, lymph node involvement, extent of node dissection, and final Gleason score, says Ward. In addition, prostate-specific antigen (PSA) levels can inform whether salvage radiation therapy should be indicated for a patient, Ward adds.
Patients with high PSA should receive an escalation in treatment, says Ward. However, each treatment decision requires a discussion with a patient to determine whether adding radiation therapy or androgen-deprivation therapy is optimal, Ward concludes.
Related Content: